Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
Paris, France, and Manchester, UK – 30 January 2025 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces an unaudited full year
ANGLE PLC (AIM: AGL, OTCQX: ANPCY) has revealed new research indicating that analysing entire tumour cells in the bloodstream, rather than solely DNA fragments, may offer a more comprehensive understanding
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces innovative groundbreaking advancements in its preclinical research program focused on P140 and the pathogenesis of autoimmune diseases.
Superior performance to laboratory test and alternative available point of care platforms
Launch of new animal multiplex assays at London Vet Show Rapid, accurate detection of six gastrointestinal disease-causing pathogens in cats and dogs
Genedrive PLC (AIM: GDR) shares dropped 10% after the announcement that CEO James Cheek has left the company by mutual agreement.
NICE recommends the Genedrive® CYP2C19-ID Kit in final guidance Genedrive® CYP2C19-ID test chosen as the preferred platform for point-of-care genotype testing prior to clopidogrel treatment for stroke patients in the
genedrive plc (AIM: GDR), the point-of-care pharmacogenetic testing company, is pleased to announce that it has received Breakthrough Device Designation from the U.S. Food and Drug Administration (“FDA”) for the Genedrive® MT-RNR1
Paris, France, and Eastleigh and Manchester, UK – 11 June 2024 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international molecular diagnostics company with a broad portfolio of integrated technologies and services, announces that the
Initial orders of the Genedrive MT-RNR1 Products for new sites in the UK
ANGLE PLC (AIM: AGL, OTCQX: ANPCY), a leader in liquid biopsy technology, has reported encouraging results from a study using its Parsortix system to predict progression-free survival among ovarian cancer
genedrive plc (AIM: GDR), the point of care pharmacogenetic testing company, today announces its intention to raise funds by means of a proposed retail offer via the Retail Capital Markets ‘REX’ portal (the